COMMUNIQUÉS West-GlobeNewswire

Nicox : accord de recherche avec Re-Vana Therapeutics pour la nouvelle generation des donneurs de NO dans une forme ophtalmique novatrice à libération prolongée
20/10/2017
Communiqué de presse Nicox : accord de collaboration de recherche avec Re-Vana Therapeutics pour des donneurs d'oxyde nitrique purs de nouvelle génération dans une forme ophtalmique novatrice d'administration à [...]
Nicox Enters Research Collaboration with Re-Vana Therapeutics on its Next Generation of Stand-alone NO-donors in a Novel Sustained Release Ophthalmic Formulation
20/10/2017
Press Release Nicox Enters Research Collaboration with Re-Vana Therapeutics on its Next Generation of Stand-alone NO-donors in a Novel Sustained Release Ophthalmic Formulation October 20, 2017 - release at 7:30 am CET [...]
Publication dans la revue Journal of Clinical Investigation Insight de données précliniques montrant l'effet protecteur du masitinib sur le système nerveux périphérique dans la SLA
19/10/2017
Paris, 19 octobre 2017 , 17h45 Publication dans la revue Journal of Clinical Investigation Insight de données précliniques montrant l'effet protecteur du masitinib sur le système nerveux périphérique dans la sclérose [...]
Preclinical data showing protective effect of masitinib on the peripheral nervous system in ALS published in the Journal of Clinical Investigation Insight
19/10/2017
Paris, 19 October 2017 , 5.45pm Preclinical data showing protective effect of masitinib on the peripheral nervous system in amyotrophic lateral sclerosis (ALS) published in the Journal of Clinical Investigation Insight [...]
XBiotech annonce le premier patient dans une étude évaluant MABp1 en association avec Onivyde(R) et 5 fluorouracile / acide folinique pour le traitement du cancer du pancréas
19/10/2017
AUSTIN, Texas, le 19 octobre 2017 (GLOBE NEWSWIRE) - XBiotech Inc. (NASDAQ : XBIT) a annoncé aujourd'hui l'inscription du premier patient pour une étude de phase I à un seul groupe évaluant la dose maximale tolérée d' [...]
De nouveaux outils de recherche préclinique apportent une réponse immunitaire humanisée pour faire progresser le développement immunothérapeutique, webinaire en direct proposé par Crown Bioscience
19/10/2017
SANTA CLARA, Californie, le 19 octobre 2017 (GLOBE NEWSWIRE) - Crown Bioscience, filiale en propriété exclusive de Crown Bioscience International (TWSE : symbole boursier 6554) et société internationale de services de [...]
Notice to convene Herantis Pharma Plc's Extraordinary General Meeting of Shareholders
19/10/2017
Notice to convene Herantis Pharma Plc's Extraordinary General Meeting of Shareholders Herantis Pharma Plc Company release 19 October 2017, 4:30 pm NOTICE TO CONVENE HERANTIS PHARMA PLC'S EXTRAORDINARY GENERAL MEETING OF [...]
Herantis Pharma Plc is planning a directed share issue to a limited number of investors and the company's directors regarding the financing of the Lymfactin Phase 2 clinical study
19/10/2017
Herantis Pharma Plc is planning a directed share issue to a limited number of investors and the company's directors regarding the financing of the Lymfactin Phase 2 clinical study Herantis Pharma Plc Company release 19 [...]
Novel Preclinical Research Tools Provide Humanized Immune Response to Advance Immunotherapeutic Development, Live Webinar Hosted by Crown Bioscience
19/10/2017
SANTA CLARA, Calif., Oct. 19, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:ticker 6554) and a global drug discovery and development services company [...]
Active Biotech's partner Teva presents new data on laquinimod for the treatment of multiple sclerosis at 7th joint ECTRIMS-ACTRIMS Meeting
19/10/2017
Lund, October 19, 2017 - Active Biotech (NASDAQ STOCKHOLM: ACTI) today announces that the collaboration partner Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) will present new data on laquinimod, an [...]
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlemen...
19/10/2017
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l' [...]
Informations relatives au nombre total de droits de vote et d'actions prévues par l'article L. 233-8 II du Code de commerce et l'article 223-16 du Règlement général de l'Autorité des Marchés Financ...
19/10/2017
Informations relatives au nombre total de droits de vote et d'actions prévues par l'article L. 233-8 II du Code de commerce et l'article 223-16 du Règlement général de l'Autorité des Marchés Financiers Sanofi Société [...]
uniQure Strengthens Intellectual Property Portfolio with Acquisition of Patent Family Providing Broad Protection of the Hyperactive Padua Variant of Factor IX (FIX-Padua)
19/10/2017
~ Issued Patent in the U.S. Covers Use of FIX-Padua in Gene Therapy ~ ~ Divisional patent applications filed to further strengthen Padua intellectual property position ~ LEXINGTON, Mass. and AMSTERDAM, the Netherlands, [...]
uniQure Announces Hemophilia B Gene Therapy Program To Enter Pivotal Study With FIX-Padua Variant in 2018
19/10/2017
~ AMT-060 with the FIX-Padua Modification (AMT-061) Demonstrates Substantial Increase in FIX Activity in Non-human Primates ~ ~ Plans to Initiate Pivotal Study with Enhanced AMT-061 in 2018 ~ ~ Achieves Alignment with [...]
Conférence de presse du mercredi à l'occasion de la Conférence mondiale sur le cancer du poumon : Progrès PD-1/PD-L1 et interventions pour prévenir et traiter le cancer du poumon
19/10/2017
YOKOHAMA, Japon, 2017-10-19 (GLOBE NEWSWIRE) -- La conférence de presse finale organisée à l'occasion de la 18 e Conférence mondiale sur le cancer du poumon (WCLC) de l'Association internationale pour l'étude du cancer [...]
HOMEVI S.A.S. ISSUES A NOTICE OF CONDITIONAL REDEMPTION OF ITS €608 MILLION 6.875% SENIOR SECURED NOTES DUE 2021 AND ITS €200 MILLION FLOATING RATE SENIOR SECURED NOTES DUE 2021
19/10/2017
Suresnes, October 19, 2017 - 9:00 am CET HomeVi S.A.S. ("HomeVi"), today announces that it has issued a notice of conditional redemption for all of its outstanding €608,000,000 6 7 / 8 % Senior Secured Notes due 2021 ( [...]
Helsinn Announces Attendance at the CPhI 2017 Conference in Frankfurt
19/10/2017
Helsinn Announces Attendance at the CPhI 2017 Conference in Frankfurt Helsinn will be attending between 24-26 October at Booth Number 61B20, Hall 6.1 on the Integrated Pharma Gold corridor Helsinn will introduce its [...]
The Board of Directors of Nexstim Plc resolved on amendments of the stock options 2016 and on a new stock option plan for the CEO
19/10/2017
Company Announcement, Helsinki, 19 October 2017 at 9:00 AM The Board of Directors of Nexstim Plc resolved on amendments of the stock options 2016 and on a new stock option plan for the CEO Stock options 2016 The Board [...]
High Seizure Frequency in Children with Dravet Syndrome Negatively Impacts Quality of Life, New International Caregiver Survey Finds
19/10/2017
Global survey of 584 caregivers of children, young adults and adults with Dravet illustrates the detrimental effect of debilitating, frequent seizures on quality of life and co-morbidities Results suggest a need for [...]

Pages